Revenues driven by recent contracts for the most advanced life saving diagnostics will expand 150 times in the next 24 months. And that is just the beginning!
Millennium Healthcare (MHCC) recently announced newly SIGNED contracts with ACO’s IPA’s and MSO’s to provide exclusive, state-of-the-art, non-invasive cardiovascular and cancer diagnostics to 1,300 locations that will escalate Millennium’s current revenues of $2 million per year to over $300 million per year.
Cardiovascular and cancer diagnostics rolling out to physician’s offices this year.
Revenues will begin rapid growth by year end.
Market size for Millennium Diagnostics is 35,000 primary care offices. The first 1,300 recently contracted with Millennium and the rest are standing in line to sign up with Millennium because:
§ Millenniums program increases physician’s revenues dramatically
§ Millennium’s diagnostics are fully paid by Medicare and are free to patients
§ Millennium’s diagnostics appeal to patients because they are life-saving, fast, painless and highly accurate
§ Millennium’s diagnostics are exclusive from Millennium only
§ The physician pays no up front capital costs
Millennium’s market cap is under $40 million today and shares are selling at under $1.00.
What will this growth do to the price of MHCC shares?
Millennium HealthCare is well positioned for explosive growth that is rarely seen.
Sentiment: Strong Buy
yes. my target is still $0. how long have they been in business? how much profit have they made? they will never make money. just another wall street overhyped PIG.
Answer: (1) They have been in business for 21 years plus. (2) They have never produced a commercial product. (3) They have survived on multiple secondary offerings and payments from pharma partners. Will they ever make money? I say yes. The partnership with Abbvie calls for substantial royalties from Elagolix which is in Phase III testing. VMAT2 is about to enter Phase III, so it is also late stage. Short at your own considerable risk, IMO.
The stock does want to go to $20+ PPS Before E P3 Results.
Positive trial results we head towards $30 as Abbvie will buy out NBIX north of $50
No reason for NBIX to be a stand alone biotech given its limited pipeline after E and VMAT2
Sentiment: Strong Buy
Elagolix is an exciting compound that seems to be superior to the current therapy, particularly in an oral tablet. The pharmacological mechanism of this pill is very clear and predictable. There are some confusion to me when Abbvie will report P3 results on Elagolix. And will Abbvie report the full results or just the top line data? If you could share the information, I would greatly appreciate. Go NBIX
"limited pipeline after E and VMAT 2"? Have you forgotten about the two novel compounds for novel indications that are working their way through the "gauntlet"? ;-))))
I like your buyout target of $50, but I think Kevy is bent on keeping VMAT2 in the US as his rice bowl.
preclinical pipeline means very little in terms of valuation. If Abbvie comes shopping their will be very little kevy and the boys will be able to do. Abbvie management team are master at takeovers.
i have been around NBIX as an investment since around 1997/98 ,,,,, long, on the side lines, long, on the side lines, long. My current position I bought in 2010 Have sold 60% of it since than.
I know management and given their track record I'll be very happy with $50 in the bank
I was being sarcastic, when I talked about the "novel" compounds and the "gauntlet" came from O'Brien talking new compounds on the last CC. Kevy has been talking about them since the Q4 2011 conference call in February 2012 and hasn't gotten anything out of development since GPR119 went to BI in 2010. I know management too and would be delirious with $50.
took the words out of my mouth
These guys have milked NBIX with their Bonuses and Stock Options for years.
Indiplon run to $65 was when?? so long ago
Orally active. Elagolix is given as a once-daily oral tablet, avoiding injection-site reaction seen with depo formulations. Elagolix can be dose-titrated and quickly discontinued if necessary.
Reversible. Because elagolix can be quickly discontinued, ovulation returns typically after the first month of cessation of therapy. Women receiving long-acting formulations of Lupron and Depo Provera can take months to see normal return to ovulation.
Rapid effect. Elagolix does not cause the initial GnRH flare effect seen with agonists (drugs that simulate GnRH which the body then shuts down via feed back loop), which can worsen symptoms near-term and take weeks or even months before they reduce symptoms.
Less side-effects. The mechanism of action of a GnRH antagonist (GnRH suppression seems to have a benign affect on changes in bone mineral density and hot flash as elagolix does not suppress estradiol levels to the effect of Lupron).
If elagolix pricing can peak at $9 to $10 per day by 2025, we arrive at a peak U.S. opportunity for elagolix in endometriosis of $800 million (800k patients x 50% penetration x $9.50 per day x 210 days). 0.8 x 5 =4 b market cap.